- Home
- PDM vs SGP Comparison
PDM vs SGP Comparison
Compare PDM & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | SGP |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 932.9M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDM | SGP |
|---|---|---|
| Price | $8.23 | $21.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $9.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 981.6K | 51.9K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,994,000.00 | N/A |
| Revenue This Year | $4.21 | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $20.15 |
| 52 Week High | $9.19 | $30.56 |
Technical Indicators
Market Signals| Indicator | PDM | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 36.44 |
| Support Level | $8.16 | N/A |
| Resistance Level | $8.78 | $26.29 |
| Average True Range (ATR) | 0.22 | 1.54 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 47.94 | 2.59 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.